These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 25231001)
1. MYCN gene amplification in patients with neuroblastic tumors. Estiar MA; Fazilaty H; Aslanabadi S; Seifi M; Varghaei P; Rezamand A Cell Mol Biol (Noisy-le-grand); 2014 Sep; 60(3):23-8. PubMed ID: 25231001 [TBL] [Abstract][Full Text] [Related]
2. [Study on MYCN gene amplification and CD44 expression in neuroblastoma]. Hu HL; He LJ Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318 [TBL] [Abstract][Full Text] [Related]
3. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index. Kobayashi C; Monforte-Munoz HL; Gerbing RB; Stram DO; Matthay KK; Lukens JN; Seeger RC; Shimada H Cancer; 2005 Jan; 103(1):174-80. PubMed ID: 15549714 [TBL] [Abstract][Full Text] [Related]
4. [Prognostic significance of MYCN amplification in children neuroblastic tumors]. Niu H; Xu T; Wang F; Chen Z; Gao Q; Yi P; Xia J Zhonghua Bing Li Xue Za Zhi; 2015 Feb; 44(2):111-7. PubMed ID: 25916642 [TBL] [Abstract][Full Text] [Related]
5. Prognostic value of MYCN and ID2 overexpression in neuroblastoma. Alaminos M; Gerald WL; Cheung NK Pediatr Blood Cancer; 2005 Dec; 45(7):909-15. PubMed ID: 16047351 [TBL] [Abstract][Full Text] [Related]
6. Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group study. Moreau LA; McGrady P; London WB; Shimada H; Cohn SL; Maris JM; Diller L; Look AT; George RE Clin Cancer Res; 2006 Oct; 12(19):5693-7. PubMed ID: 17020972 [TBL] [Abstract][Full Text] [Related]
7. Copy number gain of MYCN gene is a recurrent genetic aberration and favorable prognostic factor in Chinese pediatric neuroblastoma patients. Wang M; Zhou C; Cai R; Li Y; Gong L Diagn Pathol; 2013 Jan; 8():5. PubMed ID: 23320395 [TBL] [Abstract][Full Text] [Related]
8. High incidence of MYCN amplification in a Moroccan series of neuroblastic tumors: comparison to current biological data. Tabyaoui I; Tahiri-Jouti N; Serhier Z; El Maani K; Cherkaoui S; Al Zemmouri M; Othmani MB; Zamiati S Diagn Mol Pathol; 2013 Jun; 22(2):112-8. PubMed ID: 23628823 [TBL] [Abstract][Full Text] [Related]
9. Clinical significance of a highly sensitive analysis for gene dosage and the expression level of MYCN in neuroblastoma. Tanaka S; Tajiri T; Noguchi S; Shono K; Ihara K; Hara T; Suita S J Pediatr Surg; 2004 Jan; 39(1):63-8. PubMed ID: 14694373 [TBL] [Abstract][Full Text] [Related]
10. Correlation of MYCN amplification with MCM7 protein expression in neuroblastomas: a chromogenic in situ hybridization study in paraffin sections. Tsai HY; Hsi BL; Hung IJ; Yang CP; Lin JN; Chen JC; Tsai SF; Huang SF Hum Pathol; 2004 Nov; 35(11):1397-403. PubMed ID: 15668898 [TBL] [Abstract][Full Text] [Related]
11. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206 [TBL] [Abstract][Full Text] [Related]
12. WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in non-MYCN-amplified neuroblastoma. Masserot C; Liu Q; Nguyen E; Gattolliat CH; Valteau-Couanet D; Bénard J; Huber C; Ségal-Bendirdjian E Mol Oncol; 2016 Feb; 10(2):240-52. PubMed ID: 26482175 [TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. Asgharzadeh S; Pique-Regi R; Sposto R; Wang H; Yang Y; Shimada H; Matthay K; Buckley J; Ortega A; Seeger RC J Natl Cancer Inst; 2006 Sep; 98(17):1193-203. PubMed ID: 16954472 [TBL] [Abstract][Full Text] [Related]
14. Prediction of MYCN amplification in neuroblastoma using serum DNA and real-time quantitative polymerase chain reaction. Gotoh T; Hosoi H; Iehara T; Kuwahara Y; Osone S; Tsuchiya K; Ohira M; Nakagawara A; Kuroda H; Sugimoto T J Clin Oncol; 2005 Aug; 23(22):5205-10. PubMed ID: 16051962 [TBL] [Abstract][Full Text] [Related]
16. Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology. Nakagawa A; Matsuoka K; Okita H; Iwafuchi H; Hori H; Kumagai M Pediatr Dev Pathol; 2011; 14(2):87-92. PubMed ID: 21288077 [TBL] [Abstract][Full Text] [Related]
18. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group. Schneiderman J; London WB; Brodeur GM; Castleberry RP; Look AT; Cohn SL J Clin Oncol; 2008 Feb; 26(6):913-8. PubMed ID: 18281664 [TBL] [Abstract][Full Text] [Related]
19. Coamplification of DDX1 correlates with an improved survival probability in children with MYCN-amplified human neuroblastoma. Weber A; Imisch P; Bergmann E; Christiansen H J Clin Oncol; 2004 Jul; 22(13):2681-90. PubMed ID: 15226335 [TBL] [Abstract][Full Text] [Related]
20. Circulating MYCN DNA as a tumor-specific marker in neuroblastoma patients. Combaret V; Audoynaud C; Iacono I; Favrot MC; Schell M; Bergeron C; Puisieux A Cancer Res; 2002 Jul; 62(13):3646-8. PubMed ID: 12097268 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]